Biopharma & Life Sciences
Zevra Therapeutics Executive Compensation (FY25)
ZVRA · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Neil McFarlane | Latest say-on-pay support = June 4, 2026 |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on Zevra Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 27, 2026Latest filing (8-K): June 5, 2026
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
189 figures on this page: 186 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
More on Zevra Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Neil McFarlane: $5,355,059 → $3,782,042 (29.4% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Zevra Therapeutics' chief executive and what were they paid?
Total compensation for Neil McFarlane, President, Chief Executive Officer and Director, came to $3,782,042 in fiscal 2025. Compared with the $5,355,059 reported for fiscal 2024, McFarlane's total was 29.4% lower.
What was Zevra Therapeutics' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 99.5% of votes cast for or against in favor at the meeting held June 4, 2026.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Travis Mickle Former President, Chief Executive Officer and Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Richard Pascoe Former Chief Executive Officer and Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
R. LaDuane Clifton Chief Financial Officer, Secretary and Treasurer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Richard Pascoe Former Chief Executive Officer and Director Departed during or after this year | ◇ | — | — | ◇ | — | — | ◇ | ◇ |
Travis Mickle Former President, Chief Executive Officer and Director Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Neil McFarlane President, Chief Executive Officer and Director | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
R. LaDuane Clifton Chief Financial Officer and Treasurer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Joshua Schafer Chief Commercial Officer and Executive Vice President, Business Development | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | — not reconciled |
Christal Mickle Former Interim Chief Executive Officer Departed during or after this year Served on an interim basis | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Neil McFarlane President, Chief Executive Officer and Director | ◇ | ◇ | ◇ | — | ◇ | — | ◇ | ◇ |
Adrian Quartel Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
R. LaDuane Clifton Former Chief Financial Officer and Treasurer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
R. LaDuane Clifton Former Chief Financial Officer and Treasurer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
Neil McFarlane President, Chief Executive Officer and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Rahsaan Thompson Chief Legal Officer, Secretary and Compliance Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Neil McFarlane | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Neil McFarlane | PSU | ◇ | — | ◇ | — | — | — | — |
| Neil McFarlane | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| R. LaDuane Clifton | PSU | ◇ | — | ◇ | — | — | — | — |
| R. LaDuane Clifton | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| R. LaDuane Clifton | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Rahsaan Thompson | PSU | ◇ | — | ◇ | — | — | — | — |
| Rahsaan Thompson | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Rahsaan Thompson | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Neil McFarlane | PSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | 10/09/2033 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Rahsaan Thompson | Option | ◇ | — | ◇ | 03/31/2026 |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/31/2026 | |
| Option | ◇ | — | ◇ | 03/31/2026 | |
| Option | ◇ | — | ◇ | 03/31/2026 | |
| PSU | ◇ | ◇ | — | — | |
| PSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 03/31/2026 | |
| Option | ◇ | — | ◇ | 03/31/2026 | |
| Option | ◇ | — | ◇ | 03/31/2026 | |
| Option | ◇ | — | ◇ | 03/31/2026 | |
| Option | ◇ | — | ◇ | 02/10/2026 | |
| Option | ◇ | — | ◇ | 03/31/2026 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Tamara A. Favorito Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Alicia Secor | ◇ | — | ◇ | — | — | — | ◇ |
Thomas D. Anderson | ◇ | — | ◇ | — | — | — | ◇ |
Corey Watton | ◇ | — | ◇ | — | — | — | ◇ |
John B. Bode | ◇ | — | ◇ | — | — | — | ◇ |
Alvin Shih, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Douglas W. Calder | ◇ | — | ◇ | — | — | — | ◇ |
Wendy Dixon, Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 4, 2026 | = | ◇ | ◇ | ◇ |
| 2023 | May 13, 2024 | = | ◇ | ◇ | ◇ |
| 2020 | June 17, 2021 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Neil McFarlane (President, Chief Executive Officer and Director), FY2025 total compensation $3,782,042 (base salary $729,167) [exec_comp, SEC accession 0001434647-26-000025, filed 2026-04-20]What this page does not include
Everything above is a fact Zevra Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
189 figures on this page: 186 cited to the filing that reported them, 3 calculated from figures it prints.
186 cited to the filing
3 calculated from the filing
Documents cited
- 0001434647-26-000041Proposal 2 Ratification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm
- 0001434647-26-000025Director Compensation · Outstanding Equity Awards at Fiscal Year-End Table · Summary Compensation Table
- 0001193125-25-086293
- 0001437749-24-016275Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001437749-24-010874
- 0001437749-21-015558Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Zevra Therapeutics executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ZVRA (accessed 2026).
Short form: data: Velarion
The paid brief for Zevra Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
6 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Zevra Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}